BACKGROUND: The impact of cytogenetic abnormalities in multiple myeloma after allogeneic stem cell transplantation has not been clearly defined. This study examines whether allogeneic stem cell transplantation could be of benefit for myeloma patients with high-risk cytogenetic abnormalities. DESIGN AND METHODS: This is a retrospective multicenter analysis of the registry of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, including 143 myeloma patients transplanted between 1999 and 2008. RESULTS: The incidences of cytogenetic abnormalities were 59% for del(13q), 25% for t(4;14), 25% for del(17p) and 4% for t(14;16). When comparing the population carrying an abnormality to that without the same abnormality, no significant difference was found in progression-free survival, overall survival or progression rate. Patients were grouped according to the presence of any of the poor prognosis cytogenetic abnormalities t(4;14), del(17p) or t(14;16) (n=53) or their absence (n=32). No difference in outcomes was observed between these two groups: the 3-year progression-free survival, overall survival and progression rates were 30% versus 17% (P=0.9), 45% versus 39% (P=0.8) and 53% versus 75% (P=0.9), respectively. CONCLUSIONS: These data indicate that allogeneic stem cell transplantation could potentially be of benefit to high-risk myeloma patients.
BACKGROUND: The impact of cytogenetic abnormalities in multiple myeloma after allogeneic stem cell transplantation has not been clearly defined. This study examines whether allogeneic stem cell transplantation could be of benefit for myelomapatients with high-risk cytogenetic abnormalities. DESIGN AND METHODS: This is a retrospective multicenter analysis of the registry of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, including 143 myelomapatients transplanted between 1999 and 2008. RESULTS: The incidences of cytogenetic abnormalities were 59% for del(13q), 25% for t(4;14), 25% for del(17p) and 4% for t(14;16). When comparing the population carrying an abnormality to that without the same abnormality, no significant difference was found in progression-free survival, overall survival or progression rate. Patients were grouped according to the presence of any of the poor prognosis cytogenetic abnormalities t(4;14), del(17p) or t(14;16) (n=53) or their absence (n=32). No difference in outcomes was observed between these two groups: the 3-year progression-free survival, overall survival and progression rates were 30% versus 17% (P=0.9), 45% versus 39% (P=0.8) and 53% versus 75% (P=0.9), respectively. CONCLUSIONS: These data indicate that allogeneic stem cell transplantation could potentially be of benefit to high-risk myelomapatients.
Authors: G Schilling; T Hansen; A Shimoni; T Zabelina; J-A Pérez-Simón; J-A Simon-Perez; N C Gutierrez; W Bethge; P Liebisch; R Schwerdtfeger; M Bornhäuser; S Otterstetter; E M M Penas; J Dierlamm; F Ayuk; D Atanackovic; U Bacher; C Bokemeyer; A Zander; J San Miguel; J S Miguel; A Nagler; N Kröger Journal: Leukemia Date: 2008-04-17 Impact factor: 11.528
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Henk Lokhorst; Hermann Einsele; David Vesole; Benedetto Bruno; Jesus San Miguel; Jose A Pérez-Simon; Nicolaus Kröger; Philippe Moreau; Gosta Gahrton; Cristina Gasparetto; Sergio Giralt; William Bensinger Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: Nicolaus Kröger; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Helmut Renges; Tatjana Zabelina; Boris Fehse; Florian Tögel; Georg Wittkowsky; Rolf Kuse; Axel Rolf Zander Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau Journal: Leukemia Date: 2009-10-01 Impact factor: 11.528
Authors: Henk M Lokhorst; Bronno van der Holt; Jan J Cornelissen; Marie José Kersten; Marinus van Oers; Reinier Raymakers; Monique C Minnema; Sonja Zweegman; Gerard Bos; Nicolaas Schaap; Shulamiet Wittebol; Okke de Weerdt; Rianne Ammerlaan; Pieter Sonneveld Journal: Haematologica Date: 2015-09-04 Impact factor: 9.941
Authors: Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy Journal: Biol Blood Marrow Transplant Date: 2020-04-20 Impact factor: 5.742
Authors: Nilanjan Ghosh; Xiaobu Ye; Hua-Ling Tsai; Javier Bolaños-Meade; Ephraim J Fuchs; Leo Luznik; Lode J Swinnen; Douglas E Gladstone; Richard F Ambinder; Ravi Varadhan; Satish Shanbhag; Robert A Brodsky; Ivan M Borrello; Richard J Jones; William Matsui; Carol Ann Huff Journal: Biol Blood Marrow Transplant Date: 2017-07-12 Impact factor: 5.742
Authors: A P Nair; P Walker; A Kalff; K Bergin; J Hocking; S Avery; D J Curtis; S Patil; T Das; D Klarica; S Morgan; J Muirhead; M Gorniak; J Reynolds; A Spencer Journal: Bone Marrow Transplant Date: 2017-03-20 Impact factor: 5.483
Authors: Agnes C Fett-Conte; Andréa B Carvalho-Salles; Cristina B Vendrame; Patrícia Pedrassa; Paula C Freitas; Marileila Varella-Garcia Journal: Leuk Res Date: 2012-04-12 Impact factor: 3.156
Authors: I Ahmad; R LeBlanc; S Cohen; S Lachance; T Kiss; G Sauvageau; D C Roy; L Busque; J-S Delisle; N Bambace; L Bernard; W Sabry; J Roy Journal: Bone Marrow Transplant Date: 2015-12-21 Impact factor: 5.483